T2 Biosystems Inc (TTOO) Actualités

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid...

T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture

LEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a...

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a...

Form 8-K - Current report

Form 8-K - Current report

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a...

Form 8-K - Current report

T2 Biosystems Provides Updates on its New Product Development Pipeline Progress

LEXINGTON, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a...

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

T2 Biosystems to Attend Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

T2 Biosystems Announces Second Quarter 2024 Financial Results

LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a...